Protection against Respiratory Syncytial Virus (RSV): Current Recommendations and Options in Austria

<p><strong>An underestimated pathogen is increasingly becoming the focus of preventive medicine as the cold season begins: Respiratory Syncytial Virus (RSV) is considered one of the primary causes of severe respiratory illnesses in infants and older adults. Thanks to new medical developments, effective options are now available in Austria to specifically protect vulnerable groups from severe courses of the disease. </strong></p>
<p><strong>What is Respiratory Syncytial Virus (RSV)?</strong></p>
<p>Respiratory Syncytial Virus is a widespread virus that affects the respiratory tract. While an infection in healthy adults or older children usually presents like a common cold with a runny nose, cough, and sore throat, the pathogen can penetrate deeper into the lungs in high-risk groups. </p>
<p>There, RSV often triggers inflammation of the smallest branches of the bronchi (bronchiolitis) or pneumonia. Especially during the winter months, RSV infection is one of the leading causes of illnesses requiring hospitalization in infants. </p>
<p><strong>Why are infants and older people particularly at risk?</strong></p>
<p>The risk from RSV primarily affects two age groups whose immune systems have specific characteristics:</p>
<ul>
<li><strong>Newborns and infants:</strong> The immune system of newborns is not yet fully developed. Furthermore, the airways in infants are very narrow; inflammation and mucus buildup quickly lead to symptoms of respiratory distress. </li>
<li><strong>Adults aged 60 and over, as well as individuals with chronic conditions:</strong> The immune response declines with age (immunosenescence). If there are pre-existing heart or lung conditions (e.g., COPD, asthma, heart failure) or diabetes, the risk of courses requiring hospitalization increases significantly. </li>
</ul>
<p><strong>What protection options are available in Austria?</strong></p>
<p>Medical prevention for RSV distinguishes between two main approaches: <strong>active vaccination</strong> (activation of the body’s own immune response) and <strong>passive immunization</strong> (administration of protective antibodies).</p>
<ol>
<li><strong> Passive immunization for newborns and infants</strong></li>
</ol>
<p>For infants, passive immunization with monoclonal antibodies is available as part of the public childhood vaccination program in Austria. This involves administering ready-made antibodies directly to the child, providing immediate protection against the virus. The immunization is generally recommended for children during their first RSV season and is accessible free of charge through the public program. </p>
<ol start="2">
<li><strong> Vaccination during pregnancy (maternal immunization)</strong></li>
</ol>
<p>Pregnant women can be actively vaccinated against RSV between the 24th and 36th week of pregnancy. The antibodies produced by the mother are transferred to the unborn child via the placenta. This so-called maternal immunity protects the infant from the day of birth during the first critical months of life. </p>
<ol start="3">
<li><strong> Active vaccination for adults aged 60 and over</strong></li>
</ol>
<p>Approved vaccines for active immunization are available for older adults and individuals with certain high-risk underlying conditions. According to the recommendations of the Austrian Vaccination Plan, vaccination is recommended for individuals aged 60 and over to prevent severe respiratory infections and hospitalizations during winter. </p>
<p><strong>The ideal time for prevention</strong></p>
<p>Since the RSV season in Central Europe typically occurs during the autumn and winter months, early autumn is the optimal time for consultation and implementation of the appropriate measures. If possible, immunization should be completed before the general rise in infection numbers. </p>
<p><strong>Summary Conclusion</strong></p>
<p>Respiratory Syncytial Virus is a serious pathogen of respiratory diseases, against which targeted protective measures are available thanks to modern medicine. Whether it is passive immunization for infants, protection through vaccination during pregnancy, or active vaccination for seniors—individual options depend on age and personal risk factors. Timely clarification before the start of the infection season provides clarity and safety. </p>
<p><strong>Article by Dr. Martha Krischmann, Specialist in Pediatrics and Adolescent Medicine</strong></p>